



(51) International Patent Classification:
C07D 215/54 (2006.01) C07D 405/12 (2006.01)

(21) International Application Number:
PCT/US2021/056869

(22) International Filing Date:
27 October 2021 (27.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/106,557 28 October 2020 (28.10.2020) US
63/106,858 28 October 2020 (28.10.2020) US

(71) Applicant: CHEMOCENTRYX, INC. [US/US]; 835 Industrial Road, Suite 600, San Carlos, California 94070 (US).

(72) Inventors: LI, Shijie; 86 Los Altos Avenue, Los Altos, California 94022 (US). SINGH, Rajinder; 1832 Hillman Avenue, Belmont, California 94002 (US). SCHALL, Thomas J.; c/o 835 Industrial Road, Suite 600, San Carlos, California 94070 (US). STAEHR, Peter; c/o 835 Industrial Road, Suite 600, San Carlos, California 94070 (US).

(74) Agent: KEZER, William B. et al.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 44 Montgomery Street, 36th Floor, San Francisco, California 94104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING HIDRADENITIS SUPPURATIVA





FIG. 1

(57) Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*